Search
Moroctocog alfa
go.drugbank.com/drugs/DB13999ApprovedMoroctocog alfa is approved by Health Canada and by the European Medicines Agency for the control and prevention of hemorrhagic episodes and for routine and surgical prophylaxis in patients with hemophilia … fibrinogen to fibrin, the fibrous protein that creates the scaffold of the clot.
Products: REFACTO AF 500 IU IV ENJEKSIYONLUK COZELTI ICIN TOZ VE COZUC FLAKON, 1 ADET, REFACTO AF 250 IU IV ENJEKSIYONLUK COZELTI ICIN TOZ VE COZUCU FLAKON, 1 ADETBelantamab mafodotin
go.drugbank.com/drugs/DB15719ApprovedInvestigationalWithdrawn[L53673] Later that year in October of 2025, belantamab was granded full approval by the FDA for the a similar indication to the Health Canada one. [L54331] … In the meantime, belantamab mafodotin will be available for patients in the Risk Evaluation and Mitigation Strategy (REMS) program who can enrol in a compassionate use program.
Insulin detemir
go.drugbank.com/drugs/DB01307ApprovedInvestigationalin the body not being able to produce or synthesize the insulin needed to manage circulating blood sugar levels. … has been caused to pancreatic cells that the body is no longer able to produce insulin on its own.
Ravulizumab
go.drugbank.com/drugs/DB11580ApprovedInvestigational[A244465] It was later approved by the European Commission on July 2, 2019, for the same indications.[L39710] Ravulizumab is also used to treat myasthenia gravis. … [L39690] Ravulizumab was engineered from [eculizumab], another complement inhibitor, to increase the duration of action and reduce the frequency of drug administration.
Ginkgo biloba
go.drugbank.com/drugs/DB01381ApprovedInvestigationalNutraceutical[A232389] Most of the studies that investigate the effect of _ginkgo biloba_ use the standardized extract of _Ginkgo biloba_ (EGb) 761 (EGb761), which was developed by a German pharmaceutical company in … [A232379] _Ginkgo folium_, the leaf extract of _Ginkgo biloba_, is considered an anti-dementia drug by the World Health Organization.[A232389]
Products: EXTRACTO DE GINKO BILOBA AL 24 % EQUIVALENTE A 9.6 MG DE GLICOSIDOS FLAVONOIDES.Acetohydroxamic acid
go.drugbank.com/drugs/DB00551ApprovedInvestigationalAcetohydroxamic Acid, a synthetic drug derived from hydroxylamine and ethyl acetate, is similar in structure to urea. In the urine, it acts as an antagonist of the bacterial enzyme urease. … It is used, in addition to antibiotics or medical procedures, to treat chronic urea-splitting urinary infections.
Enfortumab vedotin
go.drugbank.com/drugs/DB13007ApprovedInvestigational[L10836] Enfortumab vedotin was later approved by the European Commission on April 13, 2022.[L42000] … 2019 under the brand name Padcev<sup>TM</sup>.
Imatinib
go.drugbank.com/drugs/DB00619ApprovedInvestigational[L42220] Imatinib was approved on February 1st ,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751] … The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient.
Mavorixafor
go.drugbank.com/drugs/DB05501ApprovedInvestigational[L50647] WHIM syndrome is caused by mutations in the _CXCR4_ gene, which leads to overactivation of CXCR4 signalling pathways.[A263652] Mavorixafor prevents the activation of CXCR4. … [L50642] It was first approved by the FDA on April 30, 2024, for the treatment of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, a genetic immunodeficiency disorder characterized
Sofosbuvir
go.drugbank.com/drugs/DB08934ApprovedInvestigationalThis is an important advantage relative to HCV drugs that target other viral enzymes such as the protease, for which rapid development of resistance has proven to be an important cause of therapeutic failure … the intent to cure, or achieve a sustained virologic response (SVR), after 12 weeks of daily therapy.